

# Marco Ventimiglia

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4056740/publications.pdf>

Version: 2024-02-01

26  
papers

427  
citations

686830

13  
h-index

794141

19  
g-index

26  
all docs

26  
docs citations

26  
times ranked

623  
citing authors

#	ARTICLE	IF	CITATIONS
1	The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 182-189.	0.9	35
2	The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases. <i>Digestive and Liver Disease</i> , 2018, 50, 675-681.	0.4	34
3	Effectiveness and safety of Ustekinumab for the treatment of Crohn's disease in real-life experiences: a meta-analysis of observational studies. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 193-203.	1.4	33
4	A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor- $\alpha$ Inhibitor-naïve and Non-naïve Patients With Crohn's Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 209-217.	0.6	30
5	Effectiveness of very low-volume preparation for colonoscopy: A prospective, multicenter observational study. <i>World Journal of Gastroenterology</i> , 2020, 26, 1950-1961.	1.4	29
6	Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 1-7.	0.6	21
7	Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multicentre study. <i>United European Gastroenterology Journal</i> , 2020, 8, 1045-1055.	1.6	21
8	Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). <i>Drugs and Aging</i> , 2020, 37, 383-392.	1.3	20
9	Factors Affecting Clinical and Endoscopic Outcomes of Placebo Arm in Trials of Biologics and Small Molecule Drugs in Ulcerative Colitis: A Meta-Analysis. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 987-997.	0.9	17
10	The Addition of an Immunosuppressant After Loss of Response to Anti-TNF $\alpha$ Monotherapy in Inflammatory Bowel Disease: A 2-Year Study. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 394-401.	0.9	16
11	A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis. <i>Digestive and Liver Disease</i> , 2018, 50, 1292-1298.	0.4	16
12	A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis. <i>Digestive and Liver Disease</i> , 2020, 52, 1461-1466.	0.4	16
13	Ustekinumab in Crohn's disease: Real-world outcomes from the Sicilian network for inflammatory bowel diseases. <i>JGH Open</i> , 2021, 5, 364-370.	0.7	15
14	A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 105-111.	1.4	14
15	SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 3041-3049.	1.4	14
16	Pouchitis in pediatric ulcerative colitis: A multicenter study on behalf of Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition. <i>Digestive and Liver Disease</i> , 2019, 51, 1551-1556.	0.4	13
17	Physicians' Knowledge and Application of Immunization Strategies in Patients with Inflammatory Bowel Disease: A Survey of the Italian Group for the Study of Inflammatory Bowel Disease. <i>Digestion</i> , 2020, 101, 433-440.	1.2	13
18	Lupus-like reactions in patients with inflammatory bowel disease treated with anti-TNFs are insidious adverse events: data from a large single-center cohort. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1102-1106.	0.6	11

#	ARTICLE	IF	CITATIONS
19	Effectiveness and safety of biologics in pediatric inflammatory bowel disease: Real-life data from the Sicilian Network. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 223-229.	0.7	11
20	Health-Related Quality of Life and Home Enteral Nutrition in Children with Neurological Impairment: Report from a Multicenter Survey. <i>Nutrients</i> , 2019, 11, 2968.	1.7	10
21	Letter: SPOSIB SB2â€™a Sicilian prospective observational study of IBD patients treated with infliximab biosimilar SB2. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 234-236.	1.9	8
22	Effectiveness of Ustekinumab on Crohnâ€™s Disease Associated Spondyloarthritis: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1381-1384.	1.4	8
23	Biosimilars: The viewpoint of Italian patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2020, 52, 1304-1309.	0.4	7
24	Effectiveness and safety of tofacitinib for the treatment of ulcerative colitis: A single-arm meta-analysis of observational studies. <i>Digestive and Liver Disease</i> , 2022, 54, 183-191.	0.4	7
25	Caregiver Social Status and Health-Related Quality of Life in Neurologically Impaired Children on Home Enteral Nutrition. <i>Nutrients</i> , 2021, 13, 1928.	1.7	5
26	How clinicians and pathologists interact concerning inflammatory bowel disease in Italy: An IG-IBD survey. <i>Digestive and Liver Disease</i> , 2018, 50, 734-736.	0.4	3